文献速递临床试验与 GCP基础与转化研究

炙甘草汤颗粒治疗射血分数保留型心力衰竭的双盲安慰剂对照随机试验方案

A double-blinded, placebo-controlled randomized trial evaluating the efficacy and safety of Zhigancao Tang granules for treating HFpEF: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2021-04-20

本研究为随机双盲安慰剂对照试验方案,计划纳入122例射血分数保留型心力衰竭患者,随机接受炙甘草汤颗粒或安慰剂治疗12周。主要结局为心脏功能,次要结局包括中医证候积分、超声心动图、6分钟步行试验、利钠肽水平及生活质量量表等。结果将评估炙甘草汤颗粒治疗该病的有效性和安全性。

要点

  • 炙甘草汤颗粒治疗HFpEF的随机双盲安慰剂对照试验方案
  • 计划纳入122例患者,干预12周,主要结局为心脏功能
  • 次要结局涵盖中医证候积分、心功能指标和生活质量

核心结论

  • 该试验结果将说明炙甘草汤颗粒治疗射血分数保留型心力衰竭是否有效且安全。

研究设计与样本

  • 随机、双盲、安慰剂对照临床试验,计划纳入122例射血分数保留型心力衰竭患者,干预12周。

关键数值与推荐

  • 主要结局为心脏功能,次要结局包括中医证候积分、超声心动图、6分钟步行试验、N末端B型利钠肽原、心房利钠肽、明尼苏达心衰生活质量量表和Lee氏量表。
  • 结局指标在基线、4周和12周评估,不良事件从基线评估至12周随访期。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is a clinical syndrome characterized by diastolic dysfunction. Despite the increasing incidence of HFpEF, there is no available therapy that reduces the mortality rate of HFpEF. Zhigancao Tang has been used traditionally for the treatment of cardiovascular diseases in China. The use of traditional Chinese medicine (TCM) is associated with improvements in clinical syndromes and quality of life of patients. A randomized clinical trial should be conducted to provide clear evidence regarding the efficacy and safety of Zhigancao Tang granules for the treatment of HFpEF. METHODS: A randomized, double-blinded, placebo-controlled clinical trial was proposed. A total of 122 patients with HFpEF will be randomly assigned to receive Zhigancao Tang granules or placebo for 12 weeks. The primary outcome measure is cardiac function. The secondary outcomes include measurement of the integral TCM syndrome score, echocardiography, 6-min walk test, N-terminal-pro hormone B-type natriuretic peptide level, atrial natriuretic peptide level, Minnesota Living with Heart Failure scale, and Lee's scale. The outcome measures will be evaluated at baseline, 4 weeks, and 12 weeks. Adverse events will be evaluated from baseline till the 12-week follow-up period. DISCUSSION: The results of this trial will demonstrate whether Zhigancao Tang granules are effective and safe for treating HFpEF. TRIAL REGISTRATION: ClinicalTrials.gov NCT04317339 . Registered on 23 March 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Zhang N, Zhao Y, Liu Y, et al. A double-blinded, placebo-controlled randomized trial evaluating the efficacy and safety of Zhigancao Tang granules for treating HFpEF: study protocol for a randomized controlled trial. Trials. 2021. PMID: 33879223. doi:10.1186/s13063-021-05232-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。